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 Abstract 
 Background: Prophylactic mastectomies in carriers of muta-
tions in  BRCA1 or  BRCA2 are becoming increasingly more ac-
cepted. We investigated the outcome after prophylactic 
mastectomy, especially regarding satisfaction with the pro-
cedure, in a monocenter study.  Methods:  BRCA1/2 mutation 
carriers and non-carriers with elevated pedigree-based can-
cer risk were followed prospectively in a structured surveil-
lance program between 2000 and 2017. A retrospective tele-
phone survey was conducted among all patients with docu-
mented prophylactic mastectomy. Complications and 
satisfaction with the decision for prophylactic mastectomy 
were recorded.  Results: 39 patients who opted for a prophy-
lactic mastectomy (38  BRCA1/2 mutation carriers and 1 non-
carrier) were interviewed. Mostly nipple-sparing mastecto-
my with reconstruction was performed (87%). Half of the pa-
tients (22/39; 56.4%) had a history of unilateral breast cancer. 
The median time since prophylactic mastectomy was 5.6 
years. While 61.5% did not report any complications, flap loss 
was seen in 15% (3/20) and moderate limitations in everyday 
life were present in 20% (7/35). An improvement in quality 
of life was noticed by 82% after prophylactic mastectomy 
and no patient expressed regret with regard to the decision. 
 Conclusions: Prophylactic mastectomy is a procedure with 
risk for long-term complications in some cases. Our results 
confirm high satisfaction with the decision and improved 
quality of life.  © 2019 S. Karger AG, Basel 
 Introduction 
 BRCA1/2 mutation carriers face a high lifelong risk for 
breast and ovarian cancer. For both genes, the breast can-
cer risk until the age of 80 years is 70%, and for ovarian 
cancer it is 40% and 17% for  BRCA1  and  BRCA2 , respec-
tively  [1] . Intensified screening programs with breast 
magnetic resonance imaging (MRI) aim to improve the 
prognosis of breast cancers through early detection, and 
there is evidence for a survival benefit by surveillance  [2] . 
But mutation carriers increasingly opt for risk-reducing 
operations of the breast. For healthy carriers, not only a 
reduction of 90–95% in the risk of subsequent breast can-
cer was shown by bilateral prophylactic mastectomy, but 
also improved overall survival was described  [3] . In pa-
tients with unilateral breast cancer, the benefit of contra-
lateral prophylactic mastectomy is less clear  [4, 5] . Prior 
to the risk-reducing surgery, comprehensive counseling 
at different time points is necessary. Counseling should 
take place in specialized centers and should contain dif-
ferent reconstruction methods, such as the use of im-
plants and autologous tissue. The decision is guided by a 
woman’s activity and plans, body shape, and personal 
preferences.
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 Satisfaction of patients depends on the esthetic out-
come, freedom from lasting symptoms with limitations 
in daily life, and reduction of anxiety after surgery. Ac-
cording to 1 meta-analysis, most patients would decide to 
have the same procedure performed again  [5] . But after 
unilateral sporadic breast cancer, reduced satisfaction of 
patients with contralateral prophylactic mastectomy with 
one or more unplanned following surgeries was described 
 [6] . In addition, more body image problems and less sex-
ual pleasure, but less anxiety and improved social activi-
ties were reported in a study of women with familial risk 
for breast cancer at 1 year after prophylactic bilateral 
breast cancer  [7] .
 With this study, we aimed to investigate the complica-
tion rate and satisfaction of carriers at the Dresden center 
of the German Consortium Hereditary Breast and Ovar-
ian Cancer (GC-HBOC) after prophylactic operations of 
the breast with and without prior breast cancer diagnosis.
 Methods 
 Between 2000 and 08/2017, all patients who fulfilled certain 
criteria of familial cancer risk were counseled interdisciplinarily, 
and molecular genetic analysis was carried out as described previ-
ously at the Dresden center of the GC-HBOC  [8] . Prophylactic 
risk-reducing operations were offered to all women with a patho-
logic mutation in  BRCA1 or BRCA2 . After consenting to partici-
pate in the study, each family was documented in the mutual da-
tabase of the GC-HBOC. Follow-up was performed for all women 
who took part in our center’s intensified surveillance program or 
by personal contact with carriers and individuals with very high 
pedigree-based risk who sought additional counseling for prophy-
lactic operations. All women after risk-reducing bilateral mastec-
tomy are offered to undergo one last MRI to rule out remaining 
breast tissue in order to objectify the surgical outcome under re-
search conditions 1 year after the procedure.
 Between 04/2017 and 08/2017, a telephone survey was con-
ducted among all patients with a documented history of prophy-
lactic surgery of the breast in our database. Altogether, 44 women 
were eligible, of whom 39 were interviewed by a breast surgeon and 
5 were lost to follow-up. The interview consisted of 18 questions 
on type of surgery, status of reconstruction, early and late compli-
cations, and number of operations ( table 1 ). Moreover, satisfac-
tion, limitations in daily life, and extent of anxiety reduction were 
enquired about ( table 1 ).
 The data cut of the database was 08/2017. Statistical analyses 
were performed with SPSS.
 Results 
 Altogether, 1,319 families were counseled at the Dres-
den center, with 330 families carrying a pathogenic muta-
tion in  BRCA1 or  BRCA2 , of which roughly 11% of the 
women at risk opted for a prophylactic mastectomy. Of 
the 39 patients with documented prophylactic mastecto-
my and a telephone interview, 38 were carriers of a patho-
genic mutation. 1 patient with prophylactic mastectomy 
without  BRCA1/2 mutation was from a family with very 
high pedigree-based risks. The median age at the time of 
the interview was 47 years. The median time since breast 
cancer in affected individuals was 7.8 years and the me-
dian time since prophylactic mastectomy was 5.6 years. 
The characteristics of the participants of the telephone 
interview are displayed in  table 2 .
 In 43.6% (17/39) of the women, an exclusively prophy-
lactic operation was performed (bilateral mastectomy in 
a healthy individual). About half of the patients (22/39; 
56.4%) were affected with unilateral breast cancer ( ta-
ble 3 ), some of whom had a primary mastectomy, e.g. af-
ter neoadjuvant chemotherapy, while others opted for a 
secondary bilateral mastectomy after initial breast-con-
serving surgery ( table 2 ). Of the 39 patients under inves-
tigation, 25 (64.1%) reported having undertaken a bilat-
eral prophylactic salpingo-oophorectomy ( table 2 ).
 Table 1.  Questionnaire for the telephone interview
Questions Spectrum of answers
Type of mastectomy MRM SM
Type of reconstruction none implant autologous tissue
Number of operations total
Complications after surgery none moderate severe
Satisfaction with cosmetic result not at all rather unsatisfied indifferent satisfied very satisfied
Pain none little moderate strong severe
Improvement of quality of life none little moderate severe
Limitations in everyday life none little moderate severe
Limitations in leisure time and activities none little moderate severe
Same decision for prophylactic surgery again? yes no different
Negative impact on family/partnership? yes no indifferent
Salpingo-oophorectomy yes no
 MRM, modified radical mastectomy; SM, subcutaneous mastectomy.
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 Most of the patients with bilateral mastectomy were 
treated with nipple-sparing subcutaneous mastectomy 
(34/39; 85%) and alloplastic or autologous reconstruc-
tion, while some wished to receive a modified bilateral 
mastectomy (10%) without reconstruction ( fig. 1 a). All of 
the latter were unilaterally affected carriers of mutations 
in  BRCA1 or  BRCA2 .
 Of the 35 patients with reconstruction, 43% (15/35) 
opted for breast implants, while 57% (20/35) were recon-
structed with autologous tissue ( fig. 1 b). Reconstruction 
with implants was mostly performed during a single sur-
gery (12/15; 80%). 2 patients needed 2 different surgeries 
and 1 patient had her implants successfully placed only 
after 4 surgeries, due to wound healing problems. For au-
tologous reconstruction, a median of 3 surgeries were 
necessary. Only 4 out of 20 patients (20%) with autolo-
gous reconstruction had their surgery completed within 
a single operation.
 Reconstruction was performed without any complica-
tions in 61.5% (24/39) of the patients and moderate com-
plication such as infection or rebleeding occurred in 11 
patients (11/39; 28.2%). 3 women (7.7%) faced severe 
complications: 2 with loss of the transplanted tissue flap 
and 1 with loss of the breast implant ( fig. 1 d). No life-
threatening complications were observed.
 Most patients were satisfied or very satisfied with the 
cosmetic outcome of their prophylactic mastectomy at 
the time of the interview (33/39; 85%). Only 4 reported 
discontent (4/39; 10%) with the cosmetic outcome and 2 
(2/39; 5.1%) would elect a different type of operation. For 
example, one of these patients would prefer a subcutane-
ous rather than a subpectoral location for her implant. 
Patients with autologous reconstruction displayed higher 
satisfaction with the result (19/20; 95%) compared to 
those operated with implant reconstruction (11/15; 
73.3%). Moreover, patients after unilateral breast cancer 
were more often satisfied with the result (16/18; 88.9%) 
than healthy carriers (14/17; 82.4%).
 In terms of long-term surgery-associated morbidity, 
59% (23/39) of the patients had no pain. Severe pain was 
not reported by any of the patients. About half of the pa-
tients experienced no limitations in everyday life (20/39; 
51.3%) or in the selection of their recreational activities 
or hobbies (25/39; 64.1%). Severe limitations were not re-
ported by any patient, moderate limitations in everyday 
life were reported by 7 patients (7/39; 18%), and moderate 
limitations in leisure time activities by 4 (4/39; 10.3%) 
( fig. 1 e). A moderate restriction in everyday life was, for 
example, that it was no longer possible to lift or carry 
Characteristics n Value
Participants, all 39
Healthy mutation carrier 17
Healthy without BRCA1/2 mutation 1
Patients with unilateral breast cancer 21
Age at time of interview, years, median (range) 39 47 (26‒75)
Time since breast cancer, years, median (range) 21 7.8 (3‒33)
Time since prophylactic mastectomy, years, median (range) 39 5.6 (1‒32)
Prophylactic salpingo-oophorectomy, yes/no 39 24/15
Prior chemotherapy, yes/no 21 17/4
Prior radiation therapy, yes/no 21 5/16
 Table 2.  Characteristics of the participants 
in the telephone interview
 Table 3.  Tumor characteristics
n
Size of tumor
Tis 1
T1 13
T2 6
T3/T4 0
Unknown 2
Total 22
Nodal status
N0 13
N1 6
Unknown 2
Total 21
Metastases
M0 22
M1 0
Unknown 0
Total 22
Tumor biology
HR+, HER2– 6
HR–, HER2– 12
HR–, HER2+ 1
HR+, HER2+ 1
Unknown 2
Total 22
HR, hormone receptor; HER2, human epidermal growth factor 
receptor 2.
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heavy weight, and in leisure time activities that a prone 
position was no longer possible.
 Improvement in quality of life was seen in 78% of pa-
tients, with reduction of anxiety being the most impor-
tant reason ( fig. 1 c). While 95% of the patients would opt 
for the same procedure again, 5.1% would choose anoth-
er type of surgery. None of the 39 individuals under in-
vestigation reported regrets in terms of their decision for 
prophylactic mastectomy ( fig. 1 f). One of the patients had 
a local recurrence, but none developed metastatic disease.
 Discussion 
 We searched our database for women with document-
ed prophylactic mastectomy after interdisciplinary coun-
seling and molecular genetic analysis of the breast cancer 
genes in our GC-HBOC center in Dresden. With about 
11%, the percentage of carriers who decided to undergo 
prophylactic mastectomy was low. About half of them 
had a history of breast cancer, although overall survival 
benefit has primarily been shown in healthy carriers. In 
the past, differences in uptake of prophylactic mastec-
tomy were reported among different cultures. Compared 
to more conservative countries such as France and Po-
land, uptake in countries such as the USA, Sweden or The 
Netherlands was higher  [9–12] . With the outing of An-
gelina Jolie in 2013, the procedure lost its taboo, and we 
noticed an increase in requests for the surgery at our cen-
ter. Only recently did another center of the GC-HBOC 
report a higher rate of prophylactic mastectomy, namely 
27% and 44% among affected and healthy  BRCA1/2 mu-
tation carriers, respectively  [13] . This difference might be 
mainly explained by the different approach they adopted 
in their study. Schott et al.  [13] sent questionnaires to all 
patients who were counseled at the center in Heidelberg, 
whereas we recorded operations that were actively com-
municated. However, cultural reasons cannot be com-
pletely excluded in comparing centers in the former 
western part of Germany with those in the former eastern 
part.
 Unplanned additional operations, wound healing 
problems, and flap loss were described as negative side 
effects in the meta-analysis of Lostumbo et al.  [5] . In a 
recent one-center study, the overall complication rate 
was reported to lie at 15.9%, with significantly less com-
plications after autologous reconstruction compared to 
alloplastic reconstruction  [14] . Generally, wound infec-
tions and seromas are more common in alloplastic breast 
implants  [14, 15] . Autologous reconstruction was re-
ported to be associated with longer hospital stays, but 
also with fewer operations, less reconstruction failures 
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Type of mastectomy
subcutaneous
mastectomy
modi ed bilateral
mastectomy
10%
39%
51%
Type of reconstruc on
without reconstruc on
reconstruc on with breast
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38%24%
22%
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 Fig. 1. Results of the telephone interview.  a Type of mastectomy,  b type of reconstruction,  c improvement of 
quality of life,  d Complications,  e Limitation in everyday life/leisure time activities,  f decision for prophylactic 
surgery. 
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(7.3 vs. 1.3%) and a shorter time to full achievement of 
reconstruction  [16–18] . Complication rates are higher 
after neoadjuvant chemotherapy or after radiation ther-
apy in smoking or obese patients  [19] . After alloplastic 
breast reconstruction, Mousa et al. [20] reported postop-
erative complications in 45% of patients, of which 29% 
occurred after prior neoadjuvant chemotherapy and 25% 
after prior radiotherapy. In 30% of patients, revisional 
surgery (closure of wound, debridement, exchange or re-
moval of implant) was needed. In our cohort, the overall 
complication rate was 38%, which might be due to the 
high percentage of women participating in the study af-
ter treatment for prior breast cancer. With the exception 
of 2 women, all patients would elect the same procedure 
again. The number of severe complications such as flap 
loss after autologous reconstruction is rather high. The 
operations took place in different hospitals all over Ger-
many. In order to guarantee high oncologic safety and 
the best possible aesthetic outcome with low complica-
tion rates, these complex operations should only be per-
formed in centers with interdisciplinary teams of onco-
logic and plastic surgeons  [21, 22] . But the patient’s wish 
is not regulated further, for instance by limited insurance 
coverage.
 In spite of complications, most women after prophy-
lactic mastectomy reported high satisfaction with their 
decision in the meta-analysis of Lostumbo et al.  [5] . 
This is in accordance with our findings. Even in cases 
of dissatisfaction with the cosmetic outcome, all our pa-
tients would opt to undergo the risk-reducing opera-
tion again.
 Satisfaction with cosmetic outcome was higher after 
autologous reconstruction, which is in accordance with 
the literature  [17, 23–27] . But due to the small numbers 
in our analysis and differences in preconditions for the 
individual woman, this implies no general advice to pre-
fer one method over the other. In our study, patients 
after unilateral breast cancer reported higher satisfac-
tion compared to healthy patients. Although this was 
expected, one other group found partly different results. 
Kazzazi et al. [24] describe higher satisfaction among 
healthy individuals or after bilateral breast cancer with 
mastectomy and reconstruction compared to those with 
unilateral breast cancer with bilateral mastectomy and 
reconstruction. As an explanation, lack of time for mak-
ing the decision for contralateral mastectomy is suggest-
ed.
 Most study participants reported improvement in 
quality of life primarily due to reduction of anxiety. Those 
with unchanged quality of life reported having taken a 
rational decision without feeling stressed by anxiety be-
fore the operation. With a mean follow-up time of 14.5 
years, a retrospective study by Frost et al. [28] found sat-
isfaction with the procedure in 70% of all patients. More-
over, increase in emotional stability and decrease in stress 
was perceived in about 25% of patients. A number of 
smaller studies with a short follow-up of 1–2 years pro-
vide similar data  [7, 28–31] , but long-term prospective 
studies are still needed for the comprehensive counseling 
of patients at high risk for breast cancer.
 The strength of our analysis lies in the qualified tele-
phone interview conducted by a breast surgeon. Especial-
ly for patients with prior unilateral breast cancer, it is 
sometimes challenging to answer questions on intention, 
number of surgeries, or type of complication. A limita-
tion of our study is the restricted follow-up of the 1,319 
families at our center. Not all families are represented 
with at least 1 participant in our intensified surveillance 
program. Therefore, underestimation of the rate of up-
take of prophylactic mastectomies is possible. Moreover, 
our sample is too small to compare the impact of type of 
mastectomy and reconstruction on complications and 
quality of life. It should also be mentioned that no vali-
dated questionnaire was used to enquire about patient 
satisfaction.
 Prophylactic mastectomy is the most effective proce-
dure to improve survival rates in healthy carriers of a mu-
tation in  BRCA1/2  and possibly also in unilaterally af-
fected carriers. As we can confirm, psychosocial benefits 
outweigh possible early and late side effects of the surgery. 
Knowledge on genetic and non-genetic risk modifiers 
might help to define individual risk and the timing of the 
procedure in the future.
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